MedPath

Healthy Weight Management Project for Overweight and Obesity Children

Not Applicable
Active, not recruiting
Conditions
Obesity
Interventions
Behavioral: Lifestyle intervention
Registration Number
NCT05482191
Lead Sponsor
Ningbo No. 1 Hospital
Brief Summary

Childhood obesity is a significant public health concern worldwide. In China, childhood obesity has dramatically increased as the economy has grown quickly over the past decades. Nonalcoholic fatty liver disease (NAFLD) is tightly associated with obesity, in China, the prevalence of NAFLD in obesity children is 40.0%,the main interventions for NAFLD are lifestyle interventions. Effective strategies to helping students lose weight and alleviate NAFLD through lifestyle interventions may help promote the physical and mental health of obese students.

This study aimed (1)to assess the effectiveness of the intervention compared with the usual practice in treating childhood overweight and obesity; (2) to determine the sustainability of the treatment in preventing overweight and obesity; (3) to help alleviate or reverse NAFLD in obesity children.

Children with overweight and obesity in six primary schools in Ningbo City, Zhejiang Province will be seleted and randomly divided into two groups: the treatment group and the usual practice group. The participants of the study were students in the third grade of primary school, and the treatment will last for one academic year. This treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • parents agree and support their children's weight loss, and students and parents have informed consent;
  • students in third grade aged 8 and 10 years old;
  • students with childhood overweight/obesity defined according to the criteria for Chinese children and adolescents.
Exclusion Criteria
  • medical history of heart disease, hypertension, diabetes, tuberculosis, asthma, hepatitis or nephritis;
  • obesity caused by endocrine diseases or side effects of drugs;
  • abnormal physical development like dwarfism or gigantism;
  • physical deformity such as severe scoliosis, pectus carinatum, limp, obvious O-leg or X-leg;
  • inability to participate in school sport activities;
  • a loss in weight by vomiting or taking drugs during the past 3 months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment groupLifestyle interventionTreatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.
Primary Outcome Measures
NameTimeMethod
change in controlled attenuation parameters (CAP)3 months,9 months , 24 months and 36 months

* CAP will be detected by Fibroscan

* caculated by terminal value minus baseline value

Change in liver stiffness measurement (LSM)3 months,9 months , 24 months and 36 months

* LSM will be detected by Fibroscan

* caculated by terminal value minus baseline value

change in body mass index (BMI)3 months,9 months , 24 months and 36 months

* weight and height will be combined to report BMI in kg/m\^2

* caculated by terminal value minus baseline value

Secondary Outcome Measures
NameTimeMethod
change in fasting insulin9 months

caculated by terminal value minus baseline value

change in body fat percentage3 months and 9 months

caculated by terminal value minus baseline value

change in blood glucose9 months

caculated by terminal value minus baseline value

Change in BMI z- score3 months,9 months , 24 months and 36 months

* BMI z- score are measures of relative weight adjusted for child age and sex

* caculated by terminal value minus baseline value

change in blood lipids9 months

* include TC, TG, LDL-C, HDL-C

* caculated by terminal value minus baseline value

change in waist circumference3 months,9 months , 24 months and 36 months

caculated by terminal value minus baseline value

change in weight3 months,9 months , 24 months and 36 months

caculated by terminal value minus baseline value

change in ALT(alanine transaminase)9 months

caculated by terminal value minus baseline value

change in cardiorespiratory endurance test3 months,9 months , 24 months and 36 months

caculated by terminal value minus baseline value

Trial Locations

Locations (1)

Ningbo First Hospital

🇨🇳

Ningbo, China

© Copyright 2025. All Rights Reserved by MedPath